Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.

Milanović D, Braun F, Weber W, Grosu AL, Behe M, Niedermann G.

BMC Cancer. 2012 Jun 13;12:242. doi: 10.1186/1471-2407-12-242.

2.

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

McKeage MJ, Baguley BC.

Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975. Review.

3.

Temporal aspects of the action of ASA404 (vadimezan; DMXAA).

Baguley BC, Siemann DW.

Expert Opin Investig Drugs. 2010 Nov;19(11):1413-25. doi: 10.1517/13543784.2010.529128. Review.

4.

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy.

Baguley BC, McKeage MJ.

Future Oncol. 2010 Oct;6(10):1537-43. doi: 10.2217/fon.10.122. Review.

PMID:
21062153
5.

Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA).

Jameson MB, Head M.

Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1315-26. doi: 10.1517/17425255.2011.614389. Epub 2011 Aug 26. Review.

PMID:
21870897

Supplemental Content

Support Center